RLAY vs RXRX
RLAY: Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases. RXRX: Recursion Pharmaceuticals is a TechBio company using proprietary AI-driven platforms and supercomputing to fundamentally transform the drug discovery and development process.
Side-by-side fundamentals
| Metric | RLAY | RXRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $17.41 | $3.95 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $3.8B | $2.1B | |
| Net margin FY2025, SEC XBRL | -1800.6% | -863.4% | RXRX higher |
| Operating margin FY2025, SEC XBRL | -1971.6% | -867.9% | RXRX higher |
| ROE FY2025, SEC XBRL | -48.8% | -57.0% | RLAY higher |
| ROA FY2025, SEC XBRL | -44.5% | -43.7% | RXRX higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.02 | RLAY lower |
| Revenue growth (YoY) as of 2026-09-02 | +23.9% | -15.1% | RLAY higher |
| Revenue CAGR (3y) SEC XBRL | +123.2% | +23.3% | RLAY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.77 | 2.56 | |
| 1-year return as of 2026-10-08 close | +184.9% | -35.1% | RLAY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.